Inactive Instrument

Green Cross Cell Corporation

Equities

A031390

KR7031390008

Biotechnology & Medical Research

Tranche Update on Green Cross Cell corporation's Equity Buyback Plan announced on March 20, 2019.

April 12, 2019 at 06:19 am

From March 20, 2019 to April 11, 2019, the company has repurchased 40,000 shares, representing 0.34% for KRW 2,001.4 million. With this, the company has completed the repurchase of 40,000 shares, representing 0.34% for KRW 2,001.4 million under the buyback announced on March 20, 2019.

Latest news about Green Cross Cell Corporation

Green Cross Cell Corporation(KOSDAQ:A031390) dropped from S&P Global BMI Index	18/11/21	CI
Green Cross Lab Cell Corporation completed the acquisition of Green Cross Cell Corporation from a group of shareholders.	26/10/21	CI
Green Cross Lab Cell Corporation entered into a definitive merger agreement to acquire Green Cross Cell Corporation from a group of shareholders for approximately KRW 510 billion.	15/07/21	CI
Tranche Update on Green Cross Cell corporation's Equity Buyback Plan announced on March 20, 2019.	12/04/19	CI
Green Cross Cell corporation's Equity Buyback announced on March 20, 2019, has closed with 40,000 shares, representing 0.34% for KRW 2,001.4 million.	10/04/19	CI
Green Cross Cell corporation announces an Equity Buyback for 40,000 shares.	20/03/19	CI
Green Cross Cell corporation authorizes a Buyback Plan.	19/03/19	CI
Sistema, Medsi and RDIF Sign Agreement with South Korean Biotechnology Company Green Cross Cell	11/09/18	CI
An undisclosed buyer cancelled the acquisition of Korea High Tech Co., Ltd. from Green Cross Cell corporation.	06/09/18	CI
Green Cross Cell corporation completed the acquisition of additional 68.8% stake in Lymphotec, Inc. from Toyo Seikan Group Holdings, Ltd..	29/04/18	CI
Green Cross Cell corporation agreed to acquire additional 68.8% stake in Lymphotec, Inc. from Toyo Seikan Group Holdings, Ltd..	29/03/18	CI
Green Cross Cell corporation cancelled the acquisition of CT (cell therapy) business from Green Cross Corporation.	22/02/18	CI
Green Cross Cell corporation announced that it has received KRW 60 billion in funding from a group of investors	28/11/17	CI
AroCell AB Signs Letter of Intent with Green Cross Cell Corporation	22/11/17	CI
Green Cross Cell corporation announced that it expects to receive KRW 60 billion in funding from a group of investors	19/11/17	CI
An undisclosed buyer agreed to acquire Korea High Tech Co., Ltd. from Green Cross Cell corporation for KRW 2.6 billion.	06/09/17	CI
Green Cross Cell corporation's Equity Buyback announced on February 23, 2017, has expired.	05/04/17	CI
Green Cross Cell corporation announces an Equity Buyback.	23/02/17	CI
Green Cross Cell corporation authorizes a Buyback Plan.	22/02/17	CI
Green Cross Cell corporation signed an agreement to acquire CT (cell therapy) business from Green Cross Corporation for KRW 7.9 billion.	22/02/17	CI
Won-Young Yoon completed the acquisition of 29.36% stake in Ildong Pharmaceutical Co., Ltd. from Green Cross Corp., Green Cross Holdings Corporation and Green Cross Cell corporation.	28/07/15	CI
Won-Young Yoon signed an agreement to acquire 29.36% stake in Ildong Pharmaceutical Co., Ltd. from Green Cross Corp., Green Cross Holdings Corporation and Green Cross Cell corporation for approximately KRW 140 billion.	28/05/15	CI
Green Cross Corporation completed the acquisition of additional 7.06% stake in ILDong Pharmaceutical Co. Ltd. from Whanin Pharmaceutical Co. Ltd..	10/12/12	CI
Green Cross Corporation agreed to acquire additional 7.06% stake in ILDong Pharmaceutical Co. Ltd. from Whanin Pharmaceutical Co. Ltd. for KRW 14.6 billion.	07/12/12	CI

Chart Green Cross Cell Corporation

Duration

Period

More charts

Company Profile

GREEN CROSS CELL CORPORATION is a Korea-based company mainly engaged in the manufacture of electronic components, through its subsidiaries. The Company operates in two business divisions: IT segment and biotechnology segment. Its IT segment exports computer peripherals to overseas markets, such as liquid crystal display (LCD) monitors. Its biotechnology segment provides immune cell therapy, immune cell cryopreservation service and cord blood cryopreservation service. Through its subsidiaries, it also involves in the manufacture of electronic components, including industrial tapes and others. On April 9, 2013, it changed its name to GREEN CROSS CELL CORPORATION from INNOCELL CORPORATION.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+18.34%	125B
REGENERON PHARMACEUTICALS, INC.	+15.06%	108B
BIONTECH SE	-6.39%	23.64B
ARGENX SE	+2.39%	22.39B
GENMAB A/S	-12.11%	17.78B
WUXI APPTEC CO., LTD.	-41.64%	16.43B
BEIGENE, LTD.	-12.07%	16.34B
NEUROCRINE BIOSCIENCES, INC.	+1.05%	13.56B
SAREPTA THERAPEUTICS, INC.	+25.87%	11.59B

Bio Therapeutic Drugs